Ракета-носитель Astra доставит полезную нагрузку NASA в этом году

BNGO Bionano Genomics, Inc. came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 8.33%. Bionano Genomics, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $7.22 million for the quarter ended September 2022, surpassing the Zacks Consensus Estimate by 7.78%. This compares to year-ago revenues of $4.66 million. The company has topped consensus revenue estimates four times over the last four quarters. Это Zacks. EPS и Rev выше ожиданий, прогнозы вроде тоже неплохие)